Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02631772 · ClinicalTrials.gov registry record · Phase 4
LIVE-C-Free: Early and Late Treatment of Hepatitis C With Sofosbuvir/Ledipasvir in Liver Transplant Recipients
A Phase 4 study, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- Phase 4
- Development phase
- 32
- Enrollment target
NCT02631772 is a Phase 4 study that has completed, run by Medical University of South Carolina. The registered enrollment target is 32 participants.
The verdict
NCT02631772, a Phase 4 study, has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 32 participants
- Enrollment target
Study Summary
The predominant remaining questions for post-transplant treatment of Hepatitis C virus (HCV) in the DAA (direct acting anti-virals) era are whether a ribavirin-free regimen is possible and whether pre-emptive treatment is now a potential option to prevent long-term damage to the allograft. Our aim is to provide answers to these primary questions with our multicenter, prospective, randomized, open-label intent-to-treat phase IV study
Interventions
- DRUG Sofosbuvir/Ledipasvir x 12 weeks
- DRUG Sofosbuvir/Ledipasvir + Ribavirin x 12 weeks
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2016-06-01 |
| Est. Completion | 2018-06-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02631772
The ClinicalTrials.gov registry entry for NCT02631772 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sofosbuvir/Ledipasvir x 12 weeks is the first listed.
NCT02631772 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02631772 about?
NCT02631772 is a clinical study titled "LIVE-C-Free: Early and Late Treatment of Hepatitis C With Sofosbuvir/Ledipasvir in Liver Transplant Recipients". The predominant remaining questions for post-transplant treatment of Hepatitis C virus (HCV) in the DAA (direct acting anti-virals) era are whether a ribavirin-free regimen is possible and whether pre-emptive treatment is now a potential option to prevent long-term damage to the allograft. Our aim ...
What is the current status of trial NCT02631772?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 32 participants. The study started on 2016-06-01. Estimated completion is 2018-06-30.
What interventions are being tested in trial NCT02631772?
The interventions under investigation include: Sofosbuvir/Ledipasvir x 12 weeks (DRUG), Sofosbuvir/Ledipasvir + Ribavirin x 12 weeks (DRUG).
Who is sponsoring clinical trial NCT02631772?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.